3-溴苯并呋喃-5-羧酸甲酯 | 501892-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 3-溴苯并呋喃-5-羧酸甲酯
• 中文别名: 3-溴苯并呋喃-5-甲酸甲酯
• 英文名称: methyl 3-bromobenzofuran-5-carboxylate
• 英文别名: methyl 3-bromo-1-benzofuran-5-carboxylate
• CAS: 501892-90-6
• 化学式: C₁₀H₇BrO₃
• 分子量: 255.068
• InChiKey: CUVRUZJEZNNRPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-溴苯并呋喃-5-羧酸甲酯 在 甲醇 、 锂硼氢 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以70%的产率得到(3-bromobenzofuran-5-yl)methanol
  参考文献：
  名称：

  [EN] ORAL COMPLEMENT FACTOR D INHIBITORS
  [FR] INHIBITEURS ORAUX DU FACTEUR D DU COMPLÉMENT

  摘要：

  揭示了式(I)的化合物及其药学上可接受的盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活性特征的疾病或状况的方法。

  公开号：

  WO2021072198A1
• 作为产物：
  描述：

  苯并呋喃-5-甲酸甲酯 在 溴 、 碳酸氢钠 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 、 甲醇 为溶剂， 反应 21.0h， 以75%的产率得到3-溴苯并呋喃-5-羧酸甲酯
  参考文献：
  名称：

  Azabicyclic compounds for the treatment of disease

  摘要：

  这项发明提供了Formula I的化合物： 其中Azabicyclo是 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对已知涉及α7的药物具有用处。

  公开号：

  US20030232853A1

文献信息

• Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
  申请人：——

  公开号：US20030105089A1

  公开（公告）日：2003-06-05

  The invention provides compounds of Formula I: 1 which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which &agr;7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.

  这项发明提供了Formula I的化合物： 1 这些化合物可以是药用可接受的盐或组合物的形式，对治疗涉及α7尼古丁型乙酰胆碱受体(nAChRs)的疾病或症状是有用的。
• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。
• GSK-3β inhibitor
  申请人：Itoh Fumio

  公开号：US08492378B2

  公开（公告）日：2013-07-23

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁唑烷化合物或其盐或前药的GSK-3β抑制剂，该抑制剂可用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种包含式（I）所表示的化合物的GSK-3β抑制剂：其中每个符号如规范中所定义，或其盐或前药。
• Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β
  作者：Morihisa Saitoh、Jun Kunitomo、Eiji Kimura、Yoji Hayase、Hiromi Kobayashi、Noriko Uchiyama、Tomohiro Kawamoto、Toshimasa Tanaka、Clifford D. Mol、Douglas R. Dougan、Garret S. Textor、Gyorgy P. Snell、Fumio Itoh

  DOI：10.1016/j.bmc.2009.01.019

  日期：2009.3

  Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3beta inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3beta.
• 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole Derivatives as Novel Inhibitors of Glycogen Synthase Kinase-3β with Good Brain Permeability
  作者：Morihisa Saitoh、Jun Kunitomo、Eiji Kimura、Hiroki Iwashita、Yumiko Uno、Tomohiro Onishi、Noriko Uchiyama、Tomohiro Kawamoto、Toshimasa Tanaka、Clifford D. Mol、Douglas R. Dougan、Garret P. Textor、Gyorgy P. Snell、Masayuki Takizawa、Fumio Itoh、Masakuni Kori

  DOI：10.1021/jm900647e

  日期：2009.10.22

  Glycogen synthase kinase 3beta (GSK-3beta) inhibition is expected to be a promising therapeutic approach for treating Alzheimer's disease. Previously we reported a series of 1,3,4-oxadiazole derivatives as potent and highly selective GSK-3beta inhibitors, however, the representative compounds 1a,b showed poor pharmacokinetic profiles. Efforts were made to address this issue by reducing molecular weight and lipophilicity, leading to the identification of oxadiazole derivatives containing a sulfinyl group, (S)-9b and (S)-9c. These compounds exhibited not only highly selective and potent inhibitory activity against GSK-3beta but also showed good pharmacokinetic profiles including favorable BBB penetration. In addition, (S)-9b and (S)-9c given orally to mice significantly inhibited cold water stress-induced tau hyperphosphorylation in mouse brain.